Marfan syndrome is caused by mutations in the FBN1 gene, located on chromosome 15. It follows an autosomal dominant inheritance pattern, meaning a single altered copy of the gene is enough to cause the condition. The specific types of mutations within FBN1 vary widely, but roughly two-thirds of cases involve missense mutations, where a single “letter” in the DNA code is swapped for another, producing a slightly altered version of the protein fibrillin-1.
The FBN1 Gene and Fibrillin-1
Fibrillin-1 is a large protein that forms the scaffolding of connective tissue throughout the body. It gives structure and elasticity to blood vessels, heart valves, bones, joints, the lens of the eye, and skin. When the FBN1 gene carries a mutation, the resulting fibrillin-1 protein is either structurally flawed or produced in insufficient quantities. Either way, connective tissue becomes weaker than normal, which explains why Marfan syndrome affects so many different organ systems at once.
Fibrillin-1 also plays a critical signaling role. Under normal conditions, it locks onto a growth factor called TGF-beta and keeps it inactive in the tissue surrounding cells. When fibrillin-1 is deficient or malformed, TGF-beta escapes that hold and becomes overactive. Excess TGF-beta signaling drives many of the progressive features of Marfan syndrome, particularly the gradual weakening and enlargement of the aorta.
Types of Mutations Found in FBN1
There is no single “Marfan mutation.” Over a thousand different FBN1 mutations have been cataloged, and they fall into several categories.
- Missense mutations (about 50–66% of cases): A single DNA base change causes one amino acid to be replaced by another in the finished protein. In Marfan syndrome, these most commonly disrupt cysteine residues, which are amino acids responsible for forming chemical bonds that hold the protein in its correct three-dimensional shape. Losing or gaining a cysteine destabilizes the protein’s structure.
- Splicing mutations (roughly 10–18%): These occur at the boundaries between coding and non-coding sections of the gene. They cause the cell’s machinery to misread where one section ends and the next begins, often resulting in entire chunks of the protein being skipped during assembly.
- Frameshift mutations (roughly 16%): Small insertions or deletions of DNA bases shift the reading frame of the genetic code, like removing a letter from the middle of a sentence and running all the remaining words together. This usually produces a garbled, shortened protein.
- Nonsense mutations (roughly 16%): A base change creates a premature “stop” signal in the gene, cutting production of the protein short. The cell often recognizes the defective message and destroys it before a protein is even made, leaving that copy of the gene essentially silent.
- Large deletions or rearrangements (rare): Occasionally, entire sections of the gene or even the whole gene are deleted. These are uncommon but do occur in a small number of patients.
Autosomal Dominant Inheritance
Marfan syndrome requires only one mutated copy of FBN1 to develop. Every person carries two copies of the gene, one from each parent. If one parent has Marfan syndrome, each child has a 50% chance of inheriting the mutated copy.
About 75% of people with Marfan syndrome inherited it from an affected parent. The remaining 25% have a de novo mutation, meaning the genetic change occurred spontaneously in them for the first time, with no family history of the condition. Once a de novo mutation exists, it can be passed on to future generations at the same 50% rate.
How the Mutation Damages the Body
Scientists have debated exactly how one bad copy of FBN1 leads to disease. Two mechanisms appear to be at work, sometimes simultaneously. In the “dominant negative” model, the mutant protein is still produced but interferes with the normal protein, disrupting the assembly of connective tissue fibers. In the “haploinsufficiency” model, the mutant copy produces little to no usable protein, and the remaining normal copy simply cannot make enough fibrillin-1 on its own. Research now suggests that haploinsufficiency, having only half the normal amount of working protein, may be the more important driver for many patients.
Regardless of the mechanism, the downstream effects are similar. Weakened connective tissue leads to the hallmark features: unusually tall stature and long fingers, lens dislocation in the eyes, and progressive widening of the aorta. The aortic involvement is the most dangerous aspect. Surgery is typically recommended when the aortic root reaches 50 millimeters in diameter, or 45 millimeters if additional risk factors are present.
Mutation Location and Severity
Where a mutation falls within the FBN1 gene can influence how severe the condition becomes. A stretch of the gene known as the “neonatal region” (roughly exons 24 through 32) is associated with the most serious early-onset disease. In one large study, 8 out of 10 patients who experienced an aortic event before age 10 had mutations located in this region. Mutations outside this zone tend to cause a broader, more variable spectrum of symptoms.
The type of mutation also correlates loosely with specific features. Patients with premature termination codons, the result of nonsense or frameshift mutations, tend to be taller on average. Missense mutations affecting cysteine residues are more strongly linked to lens dislocation. These patterns are statistical tendencies rather than hard rules, though. Two people in the same family carrying the identical mutation can still differ noticeably in which symptoms they develop and how severe those symptoms become.
How Diagnosis Works
Diagnosis follows a framework called the revised Ghent nosology, which weighs clinical findings alongside genetic testing. The two cardinal features are aortic root enlargement and lens dislocation. If both are present, the diagnosis is confirmed even without genetic testing. If only one is present, finding a known disease-causing FBN1 mutation or accumulating enough points on a systemic scoring system (which accounts for skeletal, skin, and lung features) can establish the diagnosis.
Genetic testing is not mandatory but carries increasing weight in the diagnostic process. It is especially useful in younger patients who haven’t yet developed the full range of features, in families considering genetic counseling, and in distinguishing Marfan syndrome from related connective tissue conditions caused by mutations in different genes. With regular monitoring and modern treatment, most people with Marfan syndrome now have a near-normal life expectancy, a dramatic improvement from just a few decades ago when the condition frequently shortened life significantly.